Matthew Lepoire - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Matthew Lepoire's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Matthew Lepoire
Verified
Host, Breaking Biotech
San Diego
Beats
Cryptocurrencies Indices StocksForex
Food and restaurants
Content
By Matthew Lepoire| breakingbiotech.com@ Gilead’s (#GILD) Remdesivir shows mixed results in 4 separate studies looking at treating COVID-19. The NIAID study has the most promise with a slight benefit in survival and significant benefit in time to recovery. Regeneron’s (#REGN) Kevzara on the other hand, has now been limited to “critical” COVID-19 patients and we should see a phase 3 read out in June, 2020.
By Matthew Lepoire| breakingbiotech.com@ The COVID-19 story escalates with worldwide cases hitting 100,000. In this episode of #BreakingBiotech, I talk about the concerns of the virus spreading unknowingly in the USA since the CDC has largely failed to provide the necessary resources. I also go into details about latest earnings report from Biogen (#BIIB) and breakdown an emerging immuno-oncology target (CD-47) with a focus on Trillium Therapeutics (#TRIL).
By Matthew Lepoire| breakingbiotech.com@ Gilead’s (#GILD) Remdesivir shows mixed results in 4 separate studies looking at treating COVID-19. The NIAID study has the most promise with a slight benefit in survival and significant benefit in time to recovery. Regeneron’s (#REGN) Kevzara on the other hand, has now been limited to “critical” COVID-19 patients and we should see a phase 3 read out in June, 2020.
Company Info
Breaking Biotech
San Diego, United States